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Microvolt T-Wave Alternans Identifies Patients
With Ischemic Cardiomyopathy Who Benefit
From Implantable Cardioverter-Defibrillator Therapy
Theodore Chow, MD, FACC,* Dean J. Kereiakes, MD, FACC,* Cheryl Bartone, BS,*
Terri Booth, RN,* Edward J. Schloss, MD, FACC,* Theodore Waller, MD, FACC,*
Eugene Chung, MD,* Santosh Menon, MD,* Brahmajee K. Nallamothu, MD, MPH,†
Paul S. Chan, MD, MSC†
Cincinnati, Ohio; and Ann Arbor, Michigan
Objectives This study sought to assess whether implantable cardioverter-defibrillators (ICDs) have different mortality bene-
fits among patients with ischemic cardiomyopathy who screen negative and non-negative (positive and indeter-
minate) for microvolt T-wave alternans (MTWA).
Background Microvolt T-wave alternans has been proposed as an effective tool for risk stratification. However, no studies
have examined whether ICD benefits differ by MTWA group.
Methods We developed a prospective cohort of 768 patients with ischemic cardiomyopathy (left ventricular ejection frac-
tion 35%) and no prior sustained ventricular arrhythmia, of which 392 (51%) received ICDs. The mean
follow-up time was 27  12 months. Propensity scores for ICD implantation based on the variables most likely
to influence defibrillator implantation were developed for each MTWA cohort. Multivariable Cox analyses that
controlled for propensity score, demographics, and clinical variables evaluated the degree to which ICDs de-
creased mortality risk for each MTWA group.
Results We identified 514 (67%) patients with a non-negative MTWA test result. After multivariable adjustment, ICDs were
associated with lower all-cause mortality in MTWA-non-negative patients (hazard ratio [HR] 0.45, 95% confidence
interval [CI] 0.27 to 0.76, p  0.003) but not in MTWA-negative patients (HR 0.85, 95% CI 0.33 to 2.20, p 0.73)
(for interaction, p  0.04), with the mortality benefit in MTWA-non-negative patients largely mediated through arrhyth-
mic mortality reduction (HR 0.30, 95% CI 0.13 to 0.68, p 0.004). The number needed to treat with an ICD for 2
years to save 1 life was 9 among MTWA-non-negative patients and 76 among MTWA-negative patients.
Conclusions In patients with ischemic cardiomyopathy and no prior history of ventricular arrhythmia, mortality reduction with
ICD implantation differs by MTWA status, with implications for risk stratification and health policy. (J Am Coll
Cardiol 2007;49:50–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.079t
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pudden cardiac death (SCD) accounts for one-half of all
eaths in patients with ischemic cardiomyopathy (1).
rophylactic placement of implantable cardioverter-
efibrillators (ICDs) has been shown to lower mortality
ramatically in this population (2,3). Recently, the Center
or Medicare and Medicaid Services (CMS) approved
eimbursement for ICD implantation for primary preven-
rom *The Lindner Clinical Trial Center at the Christ Hospital and the Ohio Heart
nd Vascular Center, Cincinnati, Ohio; and the †VA Ann Arbor Health Services
esearch and Development Center of Excellence, and the University of Michigan
edical School, Ann Arbor, Michigan. This study was funded in part by Medtronic.
r. Chan is supported by a National Institutes of Health Cardiovascular Multidis-
iplinary Research Training Grant and by the Ruth L. Kirchstein Research Serviceh
ward.
Manuscript received May 20, 2006, accepted June 28, 2006.ion (4,5). However, the use of left ventricular ejection
raction (LVEF) to identify patients at high and low risk for
CD is limited by its low specificity (6). As shown in the
See page 59
CD-HeFT (Sudden Cardiac Death in Heart Failure Trial)
tudy, 81% of patients with LVEF35% derived no benefit
rom ICD therapy at 5 years (2). The need for more refined
isk stratification strategies beyond simple LVEF cutoffs to
dentify further which patients are most and least likely to
enefit from ICD therapy remains great (7).
Microvolt T-wave alternans (MTWA) has been shown to
redict SCD and ventricular arrhythmic events in a number of
igh-risk populations (8). Prior studies of MTWA in patients
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January 2/9, 2007:50–8 MTWA Identifies ICD Benefitith ischemic cardiomyopathy have been limited by small
ample sizes, lack of adjustment for potential confounders, or
onmortality end points (9,10), thereby raising questions
egarding its true prognostic utility (11). In a recent study,
owever, we showed that MTWA was indeed an independent
redictor of all-cause mortality in patients with ischemic
ardiomyopathy after multivariable adjustment for demo-
raphics, clinical comorbid conditions, medication treatment,
RS duration, and Holter testing (12). Moreover, we were
ble to show that this mortality reduction was mediated
hrough reduction of arrhythmic deaths. Nevertheless, it has
een argued that the true prognostic utility of MTWA will
emain unknown unless it can be shown that ICD benefit
iffers by MTWA subgroup (11).
We therefore evaluated whether ICD benefit differed by
TWA status in ischemic cardiomyopathy patients. Spe-
ifically, because MTWA-negative patients have been
hown to have lower rates of all-cause and arrhythmic
ortality (12), we assessed whether ICD benefit occurred
nly in those higher risk patients who test MTWA-non-
egative (positive and indeterminate).
ethods
tudy population. The study design has been previously
escribed (12). Briefly, a prospective cohort of patients with
schemic cardiomyopathy was developed from 7 outpatient
ardiology clinics by the Ohio Heart and Vascular Center
nd the Lindner Clinical Trials Center. Consecutive pa-
ients who had ischemic heart disease (defined as cardiac
atheterization with 70% stenosis in at least 1 coronary
essel, documented myocardial infarction, or a history of
oronary revascularization) and LVEF 35% were enrolled
etween March 2001 and June 2004. In our prior study,
atients were followed up through December 2004. For the
resent analysis, we include follow-up data collected
hrough September 2005. Patients had to be 21 years of age
r older, to have no history of a prior ventricular arrhythmic
vent, and to be in sinus rhythm at the time of MTWA
esting. All patients gave informed consent to registry
nrollment and follow-up, and the study was approved by
he Institutional Review Board at The Christ Hospital
Cincinnati, Ohio).
TWA testing protocol. All patients underwent baseline
TWA testing by treadmill exercise at study enrollment
Heartwave system, Cambridge Heart Inc., Bedford, Mas-
achusetts) with elevation of the heart rate to a target level
f 120 beats/min. Beta-blockers and non-dihydropyridine
alcium channel blockers were withheld for 24 h before
he test. All MTWA tests were interpreted according to
tandard criteria by an expert reader blinded to patient
haracteristics and clinical outcomes (13). A positive
TWA test result was defined as sustained alternans with
n onset heart rate 110 beats/min. A negative MTWA
est result was defined as the absence of criteria for a
ositive test with a maximum heart rate 105 beats/min. all other test results were clas-
ified as indeterminate. We
lassified both indeterminate
nd positive test results as
non-negative” for statistical
nalyses based on prior studies
hat have found similar prog-
ostic utility for MTWA inde-
erminate and positive test re-
ults compared with negative
est results (8,12).
ata collection. At study en-
ollment, patient data on demo-
raphic and clinical characteristics
ere collected and included age,
ender, LVEF, QRS duration
120 ms, diabetes mellitus, hy-
ertension, symptomatic heart
ailure, chronic obstructive pulmo-
ary disease, chronic renal insufficiency, peripheral vascular
isease, and history of myocardial infarction, stroke, transient
schemic attack, atrial fibrillation, unexplained syncope, or
evascularization therapy. In addition, data on baseline medi-
ation use of aspirin, angiotensin-converting enzyme inhibitor
r angiotensin receptor blocker, beta-blocker, digoxin, diuretic,
lass I or III antiarrhythmic agent, statin, and spironolactone
ere obtained.
We also collected data on diagnostic testing with Holter
onitoring and electrophysiological study (EPS) as well as
CD implantation in the cohort. We defined nonsustained
entricular tachycardia on Holter monitoring as 100
eats/min for3 consecutive beats and30 s. Testing with
PS in the cohort was based on clinical criteria, which
ncluded age, LVEF, comorbid conditions, and noninvasive
tudies. For those patients undergoing EPS, a positive study
as defined as: 1) inducible sustained monomorphic ven-
ricular tachycardia of cycle length230 ms, or 2) inducible
entricular fibrillation, polymorphic ventricular tachycardia,
r ventricular flutter (monomorphic ventricular tachycardia
ith a cycle length 230 ms) with 2 ventricular extra-
timuli. Because not all patients underwent an EPS, 2
ummy variables were created to reflect 3 levels of EPS
tatus in the cohort: no test, a positive test, and a negative
est. Finally, ICD implantation in our cohort was primarily
93% of all ICDs implanted) based on a positive EPS, an
bnormal Holter result, or a QRS 120 ms in the period
he after the MADIT-II (Second Multicenter Automatic
efibrillator Implantation Trial-II) study (after mid 2002).
rimary end points and follow-up. The primary end point
or the study was all-cause mortality. Secondary end points
ncluded cause-specific mortality and the delivery of appro-
riate ICD shocks for confirmed ventricular tachycardia or
entricular fibrillation in patients with ICDs. Cause-specific
ortality was adjudicated by 2 study team members blinded
o the decedent’s clinical information (including MTWA
Abbreviations
and Acronyms
CI  confidence interval
CMS  Center for
Medicare and Medicaid
Services
EPS  electrophysiological
study
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
MTWA  microvolt T-wave
alternans
SCD  sudden cardiac
deathnd ICD status) and was classified as arrhythmic or nonar-
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MTWA Identifies ICD Benefit January 2/9, 2007:50–8hythmic in etiology using a modified Hinkle-Thaler system
14). Unwitnessed deaths (if stable when last observed
efore death and within 24 h), witnessed instantaneous
eaths, and deaths as a sequelae of cardiac arrest were
lassified as arrhythmic deaths. In patients with ICDs, ICD
hocks were reviewed by a physician similarly blinded to the
atient’s clinical information to determine their appropri-
teness. Clinical follow-up for mortality end points was
chieved for all patients by quarterly office visits (97.5%),
elephone contact with patient (99.4%), routine review of
ffice charts, and an annual query of the National Death
ndex (100%) (15–17).
The index date for the non-ICD cohort was the date of
nitial cohort enrollment. To avoid survival bias against
he non-ICD group (because all ICD patients had to
urvive until the time of ICD implantation), the index
ate for the ICD group was the date of ICD implanta-
ion, with the median time from cohort enrollment to
CD implantation being 58 days.
ata analysis. UNADJUSTED ANALYSES. The study cohort
as first stratified by MTWA group (negative vs. non-
egative). Baseline characteristics in ICD and non-ICD
atients for each MTWA group were compared using
tudent t tests for continuous variables and chi-square tests
or categorical variables. Survival curves between the ICD
nd non-ICD patients were constructed separately for each
TWA group using Kaplan-Meier estimates and assessed
ith univariate Cox proportional hazards analysis. Similar
nalyses were also performed for cause-specific mortality
nd for a composite end point of all-cause mortality or
ppropriate ICD shock therapy.
DJUSTED ANALYSES. To examine whether ICD benefit
iffered by MTWA group, we first evaluated for a potential
nteraction (prespecified p value 0.10) between the
TWA and ICD variables. Multivariable Cox analyses
sing a propensity score for ICD receipt (see below) in the
ntire cohort found that an interaction existed (p  0.038)
etween ICD status and MTWA test result for all-cause
ortality, suggesting that ICD benefit differed by MTWA
tatus.
Because cohort studies may have significant differences in
aseline risk between the compared groups, and because
ultivariable analyses may not adequately adjust for such
ifferences (i.e., the ICD and non-ICD patients in each
TWA group may not truly overlap in their mortality risk
rofiles), we used a propensity score analysis in our Cox
roportional hazards models (18,19). A propensity score
nalysis is a statistical technique that examines factors that
nfluence the likelihood of receiving a particular treatment
in this case, ICD implantation), thereby allowing for
omparisons of patients with comparable risk. To generate
he propensity score, multivariable logistic regression was
sed to model ICD placement (dependent variable) with the
independent variables (EPS testing, QRS duration 120
s, and abnormal Holter monitoring) most likely to influ- snce the clinical decision to implant ICDs in our cohort.
he model provides the predicted probability (from 0 to 1)
f receiving an ICD for each patient. A C-statistic, repre-
enting the area under the receiver-operating characteristic
urve, indicates how well the propensity score model pre-
icted ICD implantation.
For our study cohort, separate propensity scores were
enerated for the MTWA-negative and MTWA-non-
egative groups. For each MTWA group, separate Cox
odels were performed using their MTWA group-specific
ropensity score. First, all study covariates except the ones
sed in developing the propensity score were examined for
nivariate associations with death (p  0.10) through Cox
roportional hazards analysis. Significant variables in uni-
ariate analyses were then systematically evaluated with Cox
roportional hazards regression analyses to generate a mul-
ivariable model (p  0.05) and reported as hazard ratio
HR) with 95% confidence interval (CI). Age, LVEF, ICD
tatus, and propensity score were kept in the final model,
egardless of level of significance.
The same Cox analyses were performed to evaluate ICD
enefit for the secondary end points of arrhythmic and
onarrhythmic mortality. In addition, as a sensitivity test to
urther assess the potential mechanism of benefit with ICD
herapy, we equated an appropriate defibrillator shock in
CD patients with death, and assessed whether ICD and
on-ICD patients in each MTWA group were exposed to
similar baseline risk for mortality by comparing their risk
or a composite outcome of all-cause mortality or ICD
hock using similar Cox regression analyses as previously
escribed.
Lastly, as a sensitivity analysis, we performed the above
ox regression analyses with a full, non-parsimonious
ropensity score using all study variables to model ICD
lacement in the cohort (Appendix). We also performed
raditional multivariable Cox regression analyses without a
ropensity score to model mortality outcomes for compar-
tive purposes. Results for all-cause and cause-specific
ortality for each MTWA group did not change substan-
ively in either case.
In all models, the assumption of proportionality for the
ox proportional hazards models was visually assessed with
he (log-log [survival]) vs. log (survival time) to ensure
arallelism. All statistical analyses were performed with
AS version 9.2 (SAS Institute Inc., Cary, North Carolina).
esults
aseline characteristics and summary of study end
oints. The study cohort was composed of 768 patients, of
hich 514 patients (67%) tested MTWA non-negative and
54 (33%) tested MTWA negative. In the MTWA-non-
egative group, 317 (62%) had ICDs implanted, compared
ith 75 (30%) in the MTWA-negative group. The differ-
ntial rate of ICD implantation between the MTWA
ubgroups was caused by higher rates of EPS inducibility
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January 2/9, 2007:50–8 MTWA Identifies ICD Benefit37.7% vs. 15.0%, p  0.001), abnormal Holter studies
16.1% vs. 6.7%, p  0.001), and prolonged QRS duration
35.2% vs. 26.8%, p  0.02) in the MTWA-non-negative
ohort (Appendix).
A comparison of baseline characteristics between ICD
nd non-ICD patients for the MTWA-non-negative and
TWA-negative groups is given in Table 1 and Table 2.
mong patients who tested MTWA non-negative, those
ith ICDs were younger; more likely to be male; more likely
o have lower LVEF, EPS testing performed, EPS induc-
bility when studied, QRS 120 ms, and a history of
yocardial infarction; and more likely to be on statin,
eta-blocker, and digoxin therapy. Among patients who
ested MTWA negative, those with ICDs had lower LVEF;
ere more likely to have EPS performed, EPS inducibility
hen studied, QRS 120 ms, abnormal Holter study, and
ymptomatic heart failure; and were more likely to be on
pironolactone, digoxin, and diuretic therapy.
aseline Comparisons of ICD and Non-ICDti nts for the Cohort Testing MTWA Non-Negative
Table 1 Baseline Comparisons of ICD and Non-ICDPatients for the Cohort Testing MTWA Non-Negative
Covariates
ICD
(n  317)
Non-ICD
(n  197) p Value
Age, yrs 67.4 9.8 69.6 9.8 0.02
Gender, % male 87.1 76.7 0.004
LVEF, % 26.1 6.0 27.3 6.7 0.04
EP study performed, % (n) 74.1 (235) 40.6 (80) 0.0001
EP inducibility, % (n) 57.7 (183) 5.6 (11) 0.0001
QRS 120 ms, % 39.1 28.9 0.02
Abnormal Holter, % 17.0 14.7 0.49
CABG, % 57.4 54.8 0.57
PTCA, % 52.1 46.7 0.24
Myocardial infarction, % 88.3 78.7 0.005
Symptomatic CHF, % 75.4 70.1 0.18
History of atrial fibrillation, % 14.2 16.8 0.43
Diabetes mellitus, % 39.1 42.1 0.50
Hypertension, % 36.0 35.5 0.92
COPD, % 8.5 8.1 0.88
PVD, % 5.7 3.1 0.14
Stroke/TIA, % 16.4 18.3 0.59
Renal failure, % 2.5 3.1 0.72
Syncope, % 14.8 16.8 0.56
Medications, %
Aspirin 75.4 76.7 0.75
ACE-I or ARB 84.5 82.2 0.49
Beta-blocker 84.9 76.1 0.02
Spironolactone 17.4 15.2 0.53
Statin 64.7 53.8 0.01
Digoxin 44.2 33.0 0.01
Diuretic 65.9 65.0 0.82
Class I AA 0.3 1.0 0.37
Class III AA 8.8 9.1 0.91
A  antiarrhythmic agent; ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin
eceptor blocker; CABG  coronary artery bypass graft; CHF  congestive heart failure; COPD 
hronic obstructive pulmonary disease; EP electrophysiological; ICD implantable cardioverter-
efibrillator; LVEF left ventricular ejection fraction; MTWAmicrovolt T-wave alternans; PTCAa
ercutaneous transluminal coronary angioplasty; PVD  peripheral vascular disease; TIA 
ransient ischemic attack.The mean follow-up time was 27  12 months for the
ntire cohort (847  393 days for the non-ICD cohort;
87  350 days for the ICD cohort indexed from implant
ate). There were a total of 129 deaths (99 in the MTWA-
on-negative group and 30 in the MTWA-negative group),
f which 56 were arrhythmic (44 in the MTWA-non-
egative group and 12 in the MTWA-negative group)
Table 3). In addition, there were 35 appropriate ICD
hocks in patients who did not die in the ICD group.
nadjusted analyses. Kaplan-Meier curves comparing
verall survival between ICD and non-ICD patients for
ach MTWA group are shown in Figure 1. Univariate Cox
odels found that ICD therapy was associated with lower
ll-cause mortality in the MTWA-non-negative group (HR
.52, 95% CI 0.35 to 0.78) but not in the MTWA-negative
roup (HR 1.36, 95% CI 0.62 to 3.00) (Table 4). For
ause-specific mortality, ICD therapy in the MTWA-non-
egative group was associated with lower unadjusted ar-
hythmic mortality (HR 0.32, 95% CI 0.17 to 0.60), but had
o impact on unadjusted nonarrhythmic mortality (HR
.77, 95% CI 0.45 to 1.31). In patients testing MTWA
egative, no significant differences were seen for unadjusted
aseline Comparisons of ICD and Non-ICDti nts for the Cohort Testing MTWA Negative
Table 2 Baseline Comparisons of ICD and Non-ICDPatients for the Cohort Testing MTWA Negative
Covariates
ICD
(n  75)
Non-ICD
(n  179) p Value
Age, yrs 64.7 9.3 65.2 9.9 0.75
Gender, % male 81.3 81.0 0.95
LVEF, % 26.9 5.1 29.3 5.0 0.001
EP study performed, % (n) 54.7 (41) 11.2 (20) 0.0001
EP inducibility, % (n) 44.0 (33) 2.8 (5) 0.0001
QRS 120 ms, % 36.0 22.9 0.03
Abnormal Holter, % 17.3 2.2 0.001
CABG, % 54.7 55.9 0.86
PTCA, % 54.7 53.1 0.82
Myocardial infarction, % 88.0 86.0 0.68
Symptomatic CHF, % 80.0 63.7 0.01
History of atrial fibrillation, % 18.7 12.9 0.23
Diabetes mellitus, % 26.7 34.6 0.22
Hypertension, % 37.3 34.6 0.68
COPD, % 6.7 3.9 0.35
PVD, % 2.7 6.7 0.13
Stroke/TIA, % 8.0 12.3 0.32
Renal failure, % 1.3 3.4 0.29
Syncope, % 16.0 16.2 0.97
Medications, %
Aspirin 81.3 76.0 0.35
ACE-I or ARB 90.7 84.4 0.15
Beta-blocker 84.0 83.2 0.88
Spironolactone 26.7 12.3 0.01
Statin 69.3 64.8 0.49
Digoxin 32.0 20.7 0.05
Diuretic 72.0 60.3 0.07
Class I AA 2.7 0.0 0.16
Class III AA 6.7 7.8 0.75
bbreviations as in Table 1.rrhythmic or nonarrhythmic mortality between patients
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MTWA Identifies ICD Benefit January 2/9, 2007:50–8ith and without ICDs. When the combined end point of
ll-cause mortality and appropriate ICD shock was exam-
ned, neither MTWA group showed significant unadjusted
vent-free survival differences between the ICD groups
Table 4).
DJUSTED ANALYSES. The propensity score derived from
he 3 variables (EPS testing, QRS duration, and Holter
onitoring) most likely to predict ICD placement in our
ohort showed good discrimination, with a C-statistic of
.807 in the MTWA-non-negative group and 0.778 in the
TWA-negative group. Among MTWA-non-negative
atients, the variable most strongly associated with ICD
lacement was a positive EPS (Wald chi-square  88.6,
dds ratio 27.0, 95% CI 13.5 to 52.6), although a QRS
120 ms was also a strong predictor (Table 5). In the
TWA-negative group, a positive EPS remained the
ariable most likely to predict ICD placement (Wald
hi-square  39.5, odds ratio 27.8, 95% CI 9.8 to 76.9).
Multivariable Cox proportional hazards analyses adjusted
or the propensity score and all other study covariates
howed that ICDs were associated with significantly re-
uced all-cause mortality in MTWA-non-negative patients
HR 0.45, 95% CI 0.27 to 0.76, p  0.003) but not in
TWA-negative patients (HR 0.85, 95% CI 0.33 to 2.20,
 0.73) (Table 4). Multivariable Cox analyses for the
Summary of Study End Points for ICD andNon-ICD Patients Stratified by MTWA Test Statu
Table 3 Summary of Study End Points for ICNon-ICD Patients Stratified by MTW
Outcomes
MTWA Non
ICD
(n  317)
Mean follow-up, days  SD 790 348
Total deaths (%) 46 (14.5%)
Arrhythmic deaths (%) 15 (4.7%)
Nonarrhythmic deaths (%) 31 (9.8%)
Total deaths  shocks (%) 77 (24.3%)
Abbreviations as in Table 1.
Summary of Unadjusted and Adjusted Cox Propo
Table 4 Summary of Unadjusted and Adjust
Unadjusted Hazard Ra
(95% CI)
TWA non-negative
All-cause 0.52 (0.35–0.78)
Arrhythmic 0.32 (0.17–0.60)
Nonarrhythmic 0.77 (0.45–1.31)
All-cause  shocks 0.95 (0.67–1.35)
TWA negative
All-cause 1.36 (0.62–3.00)
Arrhythmic 1.06 (0.28–3.98)
Nonarrhythmic 1.56 (0.58–4.28)
All-cause  shocks 1.89 (0.92–3.88)
Univariate (unadjusted) and multivariable Cox proportional hazards m
cause-specific mortality are depicted. The ICD therapy reduced all-c
negative patient group, but showed no benefit in the MTWA-negative
shocks was used, there were no differences in baseline exposure risk betwee
CI  confidence interval; other abbreviations as in Table 1.ntire cohort found a statistically significant difference in
ortality reduction benefit with ICD therapy when com-
aring those testing MTWA non-negative with those
esting MTWA negative (p value for interaction term
valuating ICD mortality benefit by MTWA group 
.038). When confining the outcome to arrhythmic deaths,
CDs were associated with dramatic reductions in arrhyth-
ic mortality in the MTWA-non-negative group only (HR
.30, 95% CI 0.13 to 0.68, p  0.004). No significant
ifferences in nonarrhythmic mortality were found between
he ICD groups in either the MTWA-non-negative or
negative cohorts. Finally, when a composite outcome of
ll-cause mortality or appropriate ICD shocks was exam-
ned, ICD and non-ICD patients had similar event-free
urvival rates in the MTWA-non-negative (HR 0.79,
5% CI 0.50 to 1.26, p  0.33) and MTWA-negative
HR 1.15, 95% CI 0.48 to 2.77, p  0.76) cohorts,
uggesting that ICD and non-ICD patients were exposed
o similar baseline combined rates of mortality and
rrhythmic events.
iscussion
his study found that the mortality reduction seen with
CD therapy may not be consistent across MTWA sub-
roups, with patients testing MTWA non-negative receiv-
d
st Status
tive MTWA Negative
ICD
n  197)
ICD
(n  75)
ICD
(n  179)
96 402 772 355 903 376
3 (26.9%) 9 (12.0%) 21 (11.7%)
9 (14.7%) 3 (4.0%) 9 (5.0%)
4 (12.2%) 6 (8.0%) 12 (6.7%)
3 (26.9%) 13 (17.3%) 21 (11.7%)
al Hazards Models
x Proportional Hazards Models
Adjusted Hazard Ratio
(95% CI) p Value
0.45 (0.27–0.76) 0.003
0.31 (0.14–0.71) 0.005
0.60 (0.30–1.22) 0.16
0.79 (0.50–1.26) 0.33
0.85 (0.33–2.20) 0.73
0.94 (0.21–4.24) 0.93
1.32 (0.41–4.29) 0.64
1.15 (0.48–2.77) 0.76
djusted for propensity score and patient covariates for all-cause and
ortality through prevention of arrhythmic deaths in the MTWA-non-
hen a combined end point of all-cause mortality or appropriate ICDs
D an
A Te
-Nega
(
7
5
2
2
5rtion
ed Co
tio
odels a
ause m
group. Wn the ICD and non-ICD groups for either MTWA group.
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January 2/9, 2007:50–8 MTWA Identifies ICD BenefitFigure 1 Kaplan-Meier Curves Comparing Overall Survival Between Patients With and Without ICDs
Survival curves for all-cause mortality are separately depicted for the microvolt T-wave alternans (MTWA)-non-negative (A) and MTWA-negative (B) cohorts.
Unadjusted results suggest a benefit with implantable cardioverter-defibrillator (ICD) therapy in the MTWA-non-negative cohort only.
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MTWA Identifies ICD Benefit January 2/9, 2007:50–8ng a 55% all-cause mortality risk reduction mediated largely
hrough prevention of arrhythmic deaths. In contrast, pa-
ients who tested MTWA negative received no substantial
ortality benefit. Although prior studies have shown that
atients with ischemic cardiomyopathy testing MTWA
on-negative have higher mortality risks (9,10,12), no
tudies to date have shown that actual ICD benefit differs by
TWA subgroup in either this or other high-risk popula-
ions. It has been suggested that the true prognostic utility
f MTWA will remain unclear until ICD benefit is evalu-
ted by MTWA status (11). We found that MTWA may
ffectively risk stratify patients with ischemic cardiomyopa-
hy by identifying test subgroups receiving substantial and
inimal benefit with ICD therapy.
A particular strength of our study was our ability to show
hat the mortality reduction seen with ICD therapy in
atients testing MTWA non-negative was mediated
hrough prevention of arrhythmic deaths. The 70% arrhyth-
ic mortality reduction attributed to ICD therapy in our
tudy is similar to the 62% rate found from post hoc analyses
f the MADIT-II study (1). Adding further validity to our
ndings, we were able to show in our sensitivity analysis that
CD and non-ICD patients in each MTWA group were
xposed to similar combined mortality and SCD rates,
uggesting that our propensity score analyses successfully
atched patients with similar baseline risk for sudden
ardiac death in each MTWA group.
Adequate control of potential confounders is critical in
ohort studies, especially when differences in patient disease
everity exist. In this study, patients with ICDs in both
TWA groups were found to have lower LVEF and higher
requencies of EPS testing and EPS inducibility, which
ave been shown to be prognostic indicators of higher risk
or SCD. Although ICD patients in the MTWA-non-
egative group also had higher utilization rates for beta-
Logistic Regression Model for Propensity ScoreBased on Lik ly Variables Predicting ICD Plac m
Table 5 Logistic Regression Model for PropBased on Likely Variables Predictin
Variable Coefficient Wal
MTWA non-negative
Intercept 0.86
EPS 1.65
EPS 0.11
Holter 0.05
QRS 120 ms 1.10
MTWA negative
Intercept 0.99
EPS 1.66
EPS 0.28
Holter 0.89
QRS 120 ms 0.64
A propensity score was derived using the variables most likely to pred
result, and QRS duration 120 ms on electrocardiogram. Because n
created to reflect 3 levels of testing: no test (reference), a positive
non-negative and negative cohorts had C-statistics of 0.808 and 0.78
CI  confidence interval; OR  odds ratio; other abbreviations as inlockers, statins, and digoxin, none of these medications hignificantly predicted all-cause mortality in the final Cox
odel (not shown). The good discrimination found with
ur propensity score models for both MTWA groups
C-statistic of 0.81 and 0.78 for MTWA-non-negative and
negative patients, respectively) suggests that we successfully
odeled a patient’s likelihood to receive an ICD and were
herefore able to adequately compare ICD and non-ICD
atients with similar propensities in our study cohort. Our
bility to show that ICD and non-ICD patients in each
TWA group were exposed to similar baseline combined
ortality and sudden cardiac death event rates also strongly
upports this finding.
Although no significant differences were seen with ICD
herapy in the MTWA-negative group, our study may not
ave been adequately powered to detect a statistically
ignificant difference in this cohort. Prior studies have
epeatedly shown that patients who test MTWA negative
ave much lower arrhythmic event rates (9,10,12), and a
arger study may have found a significant although less
obust benefit with ICD therapy in the MTWA-negative
roup. For instance, to have 80% power to detect an
bsolute annual mortality risk reduction of 1.5% (50%
hat seen in the MADIT-II study) at a 2-sided significance
evel of 0.05, a sample size of 278 MTWA-negative patients
ith the same accrual and follow-up periods would have
een needed. However, such a larger study of MTWA-
egative patients is unlikely to yield an absolute risk reduc-
ion that will ultimately prove cost effective, given that these
atients have dramatically lower baseline all-cause and
rrhythmic mortality risks than MTWA-non-negative pa-
ients. Indeed, based on Kaplan-Meier survival estimates for
ll-cause mortality in the non-ICD cohort (annualized rate
f 8%), a 33% MTWA-negative screen rate, an adjusted
azard ratio of 2.24 for mortality comparing those testing
TWA non-negative versus negative (12), and the current
Score
Placement
quare OR (95% CI) p Value
— 0.001
27.0 (13.5–52.6) 0.0001
1.24 (0.77–1.99) 0.38
1.10 (0.60–1.99) 0.77
3.01 (1.66–5.46) 0.0003
— 0.001
27.8 (9.8–76.9) 0.0001
1.75 (0.62–4.95) 0.29
5.95 (1.57–22.73) 0.009
1.89 (0.75–4.79) 0.18
receipt in the cohort: electrophysiologic study (EPS), abnormal Holter
y patient underwent an EPS in the cohort, 2 dummy variables were
d a negative test. The final propensity score model for the MTWA
ctively, suggesting very good discrimination.
1.ent
ensity
g ICD
d Chi-S
10.6
88.6
0.8
0.1
13.2
4.5
39.5
1.1
6.9
0.2
ict ICD
ot ever
test, anazard ratios of 0.45 (MTWA-non-negative patients) and
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January 2/9, 2007:50–8 MTWA Identifies ICD Benefit.85 (MTWA-negative patients), the number needed to
reat for 2 years with an ICD to save 1 life would be 9
mong MTWA-non-negative patients and 76 among
TWA-negative patients (Appendix).
The ICDs have been shown to be modestly cost effective
t approximately $57,000 per quality-adjusted life-year in
atients with ischemic heart disease and left ventricular
ysfunction (20). It has been estimated that 32,000 patients
re newly eligible by the MADIT-II study criteria annually
20). This recent cost-effectiveness study showed that ICD
herapy (compared with medical therapy) is associated with
n incremental lifetime cost of approximately $90,000 for
ach patient. Thus, full implementation of the recent CMS
ecision to expand indications for ICD coverage would
ranslate into an incremental annual cost of $2.9 billion
beyond best medical therapy) just to cover all the
ADIT-II eligible patients for life—a cost likely to be
rohibitive for an increasingly resource-strained U.S. health
are system. Indeed, a recent cost-effectiveness analysis for
CD placement in the MADIT-II study population found
he current CMS strategy of making ICDs available to all
ligible patients was not cost effective compared with a
trategy of implanting ICDs only among those testing
TWA non-negative (21). In that study, ICDs were
odeled to reduce arrhythmic mortality by 62%, regardless
f MTWA status. If the rates of ICD efficacy from this
tudy had been modeled instead, the current CMS strategy
ould have been even less cost effective relative to a more
iscriminate strategy of only implanting ICDs in the
igher-risk MTWA-non-negative group (Chan et al., per-
onal communication, February 2006).
Clearly, cost-effective therapies may remain cost-
naffordable to society if the cost of the intervention is high
nd the disease burden is great. As such, the benefits of ICD
herapy need to be weighed against the potential for adverse
vents (22), and recent recalls of defective ICDs are a
eminder that the diffusion of efficacious therapies outside of
linical trial settings are not without obstacles. Moreover,
ome studies have suggested that ICD therapy may even
ecrease quality of life (23,24). Therefore, the challenge for
olicymakers and clinicians alike is to find effective risk
tratification strategies that further define which patients are
ost and least likely to benefit from ICD therapy. Ideally,
uch a strategy would identify patients who receive little to
o benefit, thereby making the intervention more cost
ffective when implemented and allowing society to lower
osts without sacrificing life. Our findings suggest that
TWA indeed may identify such a low-risk subgroup, with
s many as one-third of patients deriving minimal benefit
rom prophylactic ICD implantation. Given this, 1 poten-
ial option for patients screening MTWA negative is to
escreen annually, although data on the conversion rate from
TWA-negative to MTWA-non-negative status, as well
s the prognostic utility for such conversion, is lacking.
Our study had several limitations. As in all cohort studies,
here exists the potential for residual confounding despiteur efforts to adjust for differences between the ICD and
on-ICD groups. We did not have information on certain
ovariates (such as laboratory values) that could have af-
ected our findings. However, the use of propensity scores
ith good model discrimination is a particular strength of
ur study. Our cohort was composed of outpatients from 1
egion of the country. As such, our findings would not apply
o patients with acutely decompensated heart failure, and
ifferences in practice patterns or patient risk geographically
ay limit the generalizability of our results. Our study
ohort included only patients with ischemic heart disease,
nd therefore does not apply to patients with nonischemic
ardiomyopathy, who are also eligible for prophylactic ICD
mplantation. Although we equated appropriate ICD
hocks with mortality as part of our sensitivity analysis, we
aution that these are not equivalent end points. Therefore,
ur analyses with this combined end point should be
nterpreted as a sensitivity analysis only. Microvolt T-wave
lternans can be performed only in patients in sinus rhythm,
o our findings cannot be extrapolated to the 8% to 15% of
rial patients with ischemic cardiomyopathy in atrial fibril-
ation or flutter (2,3). Finally, our examination of whether
CD benefit differs by MTWA group was justified by a test
or interaction that was significant with a prespecified p
alue of 0.10. However, we caution that our findings should
ot be overinterpreted as justification for using MTWA
creening for ICD placement without subsequent validation
n larger cohort studies or future randomized clinical trials,
n which ICD benefit can conclusively be shown to differ by
TWA status and potential residual confounding can be
inimized.
onclusions. In patients with ischemic cardiomyopathy,
CDs were associated with lower all-cause and arrhythmic
ates of mortality in patients testing MTWA non-negative
ut not in patients testing MTWA negative. Our findings
uggest that MTWA may be an effective risk stratification
ool in identifying patients most and least likely to benefit
rom ICD therapy, with potential policy implications for
CD coverage.
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APPENDIX
or the alternative multivariable Cox regression analyses, rates for ICD
mplantation in the MTWA groups, and the number needed to treat to save
life, please see the online version of this article.
